January 2003

**Allosteric α1-adrenoreceptor antagonism by the conopeptide ρ-TIA**

Iain A. Sharpe  
*University of Queensland*

Linda Thomas  
*University of Queensland*

Marion L. Loughnan  
*University of Queensland*

Leonid Motin  
*RMIT University*

Elka Palant  
*Xenome Ltd*

*See next page for additional authors*

Follow this and additional works at: [https://ro.uow.edu.au/ihmri](https://ro.uow.edu.au/ihmri)

Part of the Medicine and Health Sciences Commons

**Recommended Citation**  
Sharpe, Iain A.; Thomas, Linda; Loughnan, Marion L.; Motin, Leonid; Palant, Elka; Croker, Daniel E.; Alewood, Dianne; Chen, Songhai; Graham, Robert M.; Alewood, Paul F.; Adams, David J.; and Lewis, Richard J., "Allosteric α1-adrenoreceptor antagonism by the conopeptide ρ-TIA" (2003). *Illawarra Health and Medical Research Institute*. 685.  
[https://ro.uow.edu.au/ihmri/685](https://ro.uow.edu.au/ihmri/685)

Research Online is the open access institutional repository for the University of Wollongong. For further information contact the UOW Library: research-pubs@uow.edu.au
Allosteric α1-adrenoreceptor antagonism by the conopeptide ρ-TIA

Abstract
A peptide contained in the venom of the predatory marine snail Conus tulipa, ρ-TIA, has previously been shown to possess α1,-adrenoreceptor antagonist activity. Here, we further characterize its pharmacological activity as well as its structure-activity relationships. In the isolated rat vas deferens, ρ-TIA inhibited α1,-adrenoreceptor-mediated increases in cytosolic Ca2+ concentration that were triggered by norepinephrine, but did not affect presynaptic α2-adrenoreceptor-mediated responses. In radioligand binding assays using [125I]HEAT, ρ-TIA displayed slightly greater potency at the α1B, than at the α1A or α1D, subtypes. Moreover, although it did not affect the rate of association for [3H]prazosin binding to the α1B-adrenoreceptor, the dissociation rate was increased, indicating non-competitive antagonism by ρ-TIA. N-terminally truncated analogs of ρ-TIA were less active than the full-length peptide, with a large decline in activity observed upon removal of the fourth residue of ρ-TIA (Arg 4). An alanine walk of ρ-TIA confirmed the importance of Arg 4 for activity and revealed a number of other residues clustered around Arg4 that contribute to the potency of ρ-TIA. The unique allosteric antagonism of ρ-TIA resulting from its interaction with receptor residues that constitute a binding site that is distinct from that of the classical competitive α1,-adrenoreceptor antagonists may allow the development of inhibitors that are highly subtype selective.

Disciplines
Medicine and Health Sciences

Publication Details
Sharpe, I. A., Thomas, L., Loughnan, M., Motin, L., Palant, E., Croker, D. E., Alewood, D., Chen, S., Graham, R. M., Alewood, P. F., Adams, D. J. & Lewis, R. J. (2003). Allosteric α1-adrenoreceptor antagonism by the conopeptide ρ-TIA. Journal of Biological Chemistry, 278 (36), 34451-34457.

Authors
Iain A. Sharpe, Linda Thomas, Marion L. Loughnan, Leonid Motin, Elka Palant, Daniel E. Croker, Dianne Alewood, Songhai Chen, Robert M. Graham, Paul F. Alewood, David J. Adams, and Richard J. Lewis

This journal article is available at Research Online: https://ro.uow.edu.au/ihmri/685
A peptide contained in the venom of the predatory marine snail Conus tulipa, ρ-TIA, has previously been shown to possess α1-adrenoreceptor antagonist activity. Here, we further characterize its pharmacological activity as well as its structure-activity relationships. In the isolated rat vas deferens, ρ-TIA inhibited α1-adrenoreceptor-mediated increases in cytosolic Ca\(^{2+}\) concentration that were triggered by norepinephrine, but did not affect presynaptic α2-adrenoreceptor-mediated responses. In radioligand binding assays using \(^{[125]}\)IHEAT, ρ-TIA displayed slightly greater potency at the α1B than at the α1A or α1D subtypes. Moreover, although it did not affect the rate of association for \(^{[3]}\)Hprazosin binding to the α1A adrenoreceptor, the dissociation rate was increased, indicating non-competitive antagonism by ρ-TIA. N-termially truncated analogs of ρ-TIA were less active than the full-length peptide, with a large decline in activity observed upon removal of the fourth residue of ρ-TIA (Arg\(^{4}\)). An alanine walk of ρ-TIA confirmed the importance of Arg\(^{4}\) for activity and revealed a number of other residues clustered around Arg\(^{4}\) that contribute to the potency of ρ-TIA. The unique allosteric antagonism of ρ-TIA resulting from its interaction with receptor residues that constitute a binding site that is distinct from that of the classical competitive α1-adrenoreceptor antagonists may allow the development of inhibitors that are highly subtype selective.

α1-Adrenoceptors, members of the G protein-coupled receptor superfamily, are the predominant mediators of the response to norepinephrine released from the sympathetic nerves that innervate resistance vessels (1). Norepinephrine release modulates vascular tone and, as such, α1-adrenoceptors are critically involved in circulatory homeostasis. Several α1-adrenoceptor antagonists, such as the quinazoline derivative, prazosin, are widely used for the treatment of hypertension. α1-Adrenoceptor antagonists are also used to treat bladder outlet obstruction in benign prostatic hyperplasia (for review, see Ref. 2) because of their ability to relax smooth muscle.

Nevertheless, the α1-adrenoreceptor ligands developed to date interact largely with residues of the transmembrane segments that are homologous between the various receptor subtypes, rather than with residues forming the framework regions (the intra- and extracellular loops). It is not surprising, therefore, that available agonists, and also antagonists, show limited subtype selectivity (affinities differing by 50-fold or less between the various subtypes). For this reason, we sought to identify novel ligands that are likely to interact allosterically and, thus, more likely with the framework residues that are distinct between the three α1-adrenoreceptor subtypes (α1A, α1B, and α1D).

The venoms of cone snails (marine gastropods of the genus Conus) contain bioactive peptides that disrupt neurotransmission. These compounds are referred to generically as "conopeptides" or "conotoxins." Individual conopeptides typically act with a high degree of specificity, yet collectively these toxin peptides possess an extraordinarily diverse spectrum of pharmacological activities. This has made cone snail venoms an attractive resource for the discovery of novel pharmacological agents for use as therapeutics or as research tools. Classes of conopeptides that target voltage-sensitive Ca\(^{2+}\) (the ω-conopeptides), Na\(^{+}\) (µ-, γ-, and δ-conopeptides), and K\(^{+}\) (α- and κA-conopeptides) channels, and nicotinic acetylcholine (α-, αA-, and ψ-conopeptides), 5-HT\(_{3}\) (σ-conopeptides), N-methyl-D-aspartic acid (conantokins), vasopressin (conopressins), and neurotoxin (contulakins) receptors have been identified (for review, see Ref. 3). Two further classes of conopeptides that target the norepinephrine transporter (χ-conopeptides) and the α1-adrenoreceptor (ρ-conopeptides) have recently been reported by us (4). The prototypical member of the ρ-conopeptide class is ρ-TIA, which acts as an α1-adrenoceptor antagonist. This action at the receptor contrasts with other conopeptides presently known to target G protein-coupled receptors, which act as agonists. The endogenous ligands of these receptors are peptides, and, not surprisingly, these conopeptides possess amino acid sequences that display high homologies with them.

Here, we investigated the mode of action of ρ-TIA, its selectivity for α1-adrenoceptor subtypes, and its structure-activity relationships. ρ-TIA is a nineteen amino acid peptide, with four cysteine residues and an amidated C terminus. The spacing of the cysteine residues is such that there are two intercysteine regions (i.e. in the conformation CC----CC----C), and two intramolecular disulfide bonds connect the first and third and the second and fourth cysteine residues, respectively. Structurally, ρ-TIA closely resembles members of the ω-conopeptide class. The similarity, however, does not extend to their pharmacological activity. The ω-conopeptides act as competitive antagonists of muscle and neuronal nicotinic ACh receptors. The most
obvious difference between the sequences of p-TIA and the α-conopeptides is that the N-termini in the region outside of the cytine-bracketed loops. The majority of α-conopeptides have only a single N-terminal residue preceding the first cytine residue. A few other α-conopeptides have been found with zero, two, or three leading residues (5–7), but only one α-conopeptide isolated to date has four pre-cytine N-terminal residues (8), as found in p-TIA. Suspecting that this region may play an important role in conferring α-conopeptide antagonist activity on p-TIA, we examined the effect of the sequential removal of the first four amino acid residues of p-TIA on the activity of the peptide. Further information on the structure-activity relationship of p-TIA was provided by examining the effect of systematically substituting each non-cytine residue with alanine.

**EXPERIMENTAL PROCEDURES**

**Peptide Synthesis**—C-terminal amidated p-TIA and truncated analogs equivalent to residues 2–19, 3–19, 4–19, 5–19, and 1–5 of p-TIA were manually synthesized using t-butycarbonyl chemistry and cleaved from the resin following procedures described previously (9, 10). The amino acid sequences of the synthesized peptides are listed in Table I. Dinitrophenyl group removal from the histidine residue was accomplished off resin. The reduced peptides (50 mg), dissolved in a 10-mL solution of 6 mM guanidine HCl, 100 mM Tris, pH 8.2, containing disopropylethylamine (1 mL) and β-mercaptoethanol (2 mL), were stirred for 2 h at 4°C. The mixture was then acidified to pH 3 with trifluoroacetic acid and purified by preparative HPLC. The pure reduced peptides were oxidized in 0.33 M NH4OAc, 0.5 M guanidine HCl, pH 7.8, in the presence of reduced and oxidized glutathione as previously described (9). The activation of the Cys1-Cys8, Cys2-Cys4, and Cys3-Cys4 pattern of disulfide connectivity by p-TIA and the truncated analogs was verified by NMR techniques. Analogs of p-TIA in which single residues were replaced with alanine were synthesized from Fmoc chemistry. The chain assembly of the peptides was performed on a manual shaker system using HBTU activation protocols (10) to couple the Fmoc-protected amino acid to the resin. The Fmoc protecting group was removed using 50% piperidine in dimethylformamide, and dimethylformamide was used as both the coupling solvent and for flow washes throughout the cycle. The progress of the assembly was monitored by quantitative ninhydrin monitoring (11). Peptide was deprotected and cleaved from the resin by stirring at room temperature in trifluoroacetic acid/H2O/trisopropylsilane/EDT (90:5.2:5.2:1.5) for 2–3 h. Cold diethyl ether was then added to the mixture and the peptide precipitated. The precipitate was collected by centrifugation and subsequently washed with further cold diethyl ether to remove scavengers. The final product was dissolved in 50% aqueous acetonitrile and lyophilized to yield a fluffy white solid. The crude, reduced peptide was examined by reverse phase HPLC for purity, and the correct molecular weight confirmed by electrospray mass spectrometry. Pure, reduced peptides were oxidized, and the major peak was purified to >95% purity and characterized by HPLC prior to further use.

**Isolated Rat Vas Deferens—Vasa deferentia** were excised from male Wistar rats (250–350 g) killed by a blow to the head, and exsanguinated. Epididymal and prostatic portions were bisected transversely prior to further use. Isolated rat vas deferens elicited by exogenously applied norepinephrine was established by NMR techniques. Analogs of p-TIA and the truncated analogs was verified by HPLC.

**Table I. Dinitrophenyl group removal from the histidine residue was** determined by the method of Bradford (19).

**Membrane Preparation and DNA Constructs—**Eukaryotic expression vector plasmid DNA incorporating α1-adrenoreceptor cDNA in the modified eukaryotic expression vector pMT2 was used as both the coupling solvent and for flow washes throughout the cycle. The protein concentration of the prepared membranes was determined by the method of Bradford (19).

**Radioligand Binding Assays—**To determine the α1-adrenoreceptor subtype selectivity of p-TIA, the effect of p-TIA on the binding of the radiolabeled α1-adrenoreceptor antagonist [3H]HEAT was examined. 

**Fresh solution. Bovine serum albumin (1 mg/ml) was added, and the cell suspension was kept at 4°C for 2 h. Cells were then plated on 25 mm round glass cover-slips in Petri dishes containing Dulbecco’s modified Eagle’s medium and used within 48–72 h.

**Fura-2 Fluorometric Measurements—**Cover-slips holding cells were mounted in a recording chamber and constantly perfused with bath solution containing (mM): NaCl, 150; KCl, 5; CaCl2, 1; MgCl2, 1; pH 7.4 at 37°C. The tissue pieces were then cut into smaller fragments and further incubated in fresh. Membrane Preparation and DNA Constructs—COS-1 cells (ATCC; Manassas, VA) were cultured in Dulbecco’s modified Eagle’s medium containing penicillin, streptomycin, glutamine, and 5% fetal bovine serum. At 60–80% confluency, the cells were transiently transfected with plasmid DNA incorporating α1-adrenoreceptor cDNA in the modified eukaryotic expression vector pMT2 using the DEAE-dextran method (14), as previously described (15). In some experiments, COS-7 cells (ECACC; Salisbury, Wiltshire, UK) were used. These were cultured in Dulbecco’s modified Eagle’s medium containing 10% fetal bovine serum and transiently transfected with the α1-adrenoreceptor 1A-adrenoreceptor subtype (16), one for the hamster α1A-adrenoreceptor subtype (17), and another for the rat α1A-adrenoreceptor subtype (18). Membrane preparations were prepared 24 h post-transfection as described previously (18), and resuspended in HEM buffer (20 mM HEPES, 1.5 mM CaCl2, 1.5 mM MgCl2, pH 7.4) at a concentration of 10% at −80°C. The protein concentration of the prepared membranes was determined by the method of Bradford (19).

**Radioligand Binding Assays—**To determine the α1-adrenoreceptor subtype selectivity of p-TIA, the effect of p-TIA on the binding of the radiolabeled α1-adrenoreceptor antagonist [3H]HEAT was examined. 

**Fresh solution. Bovine serum albumin (1 mg/ml) was added, and the cell suspension was kept at 4°C for 2 h. Cells were then plated on 25 mm round glass cover-slips in Petri dishes containing Dulbecco’s modified Eagle’s medium and used within 48–72 h.
was determined in the presence of 100 μM phenotamine. Reactions were stopped by the addition of ice-cold HEM buffer, and the tubes' contents were filtered under vacuum onto Whatman GF/C glass filters with a Brandel cell harvester. The filters were washed 5 times with ice-cold HEM buffer, and the amount of filter-bound radioactivity was determined using a Packard Auto-γ 500 counter.

In other binding experiments, [3H]prazosin was used as the radioligand. To examine the effect of ρ-TIA on the rate of dissociation of [3H]prazosin to the α1A-adrenoceptor, reactions containing [3H]prazosin (0.25 nM), membranes from COS-7 cells transiently transfected with the α1A-adrenoceptor (2.5 μg protein), HEM buffer were set up in duplicate in the absence and presence of ρ-TIA (17.5 nM). The amount of nonspecific binding was determined as described above. Binding was allowed to proceed for 0–80 min. The effect of ρ-TIA on the rate of dissociation of [3H] prazosin from the α1A-adrenoceptor was investigated in assays where phenotamine (100 μM) and without p-TIA (10 μM) was added to reactions containing [3H]prazosin (0.43 nM) and α1A-adrenoceptor membranes (7 μg protein) that had previously been incubated for 60 min. In experiments with alanine-substituted analogs of ρ-TIA, [3H]prazosin (0.43 nM) and α1A-adrenoceptor membranes (7 μg protein) were incubated for 60 min with increasing concentrations of peptide (10−11−10−5 M). The reaction volume was 150 μl. Membranes were harvested onto Whatman GF/B filters using a Tomtec harvester. BetaPlate scintillant (PerkinElmer Life Sciences) was applied and the filter-bound radioactivity detected using a Wallac MicroBeta counter.

**Statistics and Data Analysis**—Curves were fitted to the individual data points of sets of 3–6 separate experiments by non-linear regression using Prism 3 software for Macintosh (GraphPad Software, San Diego, CA). Results are expressed as means ± S.E. Student’s t test was used to compare the curve-fitting parameters between treatments, and analysis of variance with post hoc t tests performed by the Tukey method was used for multiple comparisons. Values of p < 0.05 were considered significant.

**Materials**—Adenosine 5′-triphosphate disodium salt, (−)-norepinephrine bitartrate salt, phenolamine hydrochloride, and prazosin hydrochloride were obtained from Sigma. Collagenase type B and 1,4-dithiothreitol were obtained from Roche Applied Science. Fura-2, AM, and Fluoro-1B-adrenoreceptor membranes (7 μg protein) were incubated for 60 min with increasing concentrations of peptide (10−11−10−5 M). The reaction volume was 150 μl. Membranes were harvested onto Whatman GF/B filters using a Tomtec harvester. BetaPlate scintillant (PerkinElmer Life Sciences) was applied and the filter-bound radioactivity detected using a Wallac MicroBeta counter.

**RESULTS**

**α1-Adrenoceptor Antagonism**—The application of norepinephrine (1 μM) to dissociated smooth muscle cells from the *vasa deferentia* of adult rats elicited an increase in the intracellular free Ca²⁺ concentration (ICa²⁺) from 19 ± 3.3 nM to 130 ± 26 nM (n = 9). In cells from juvenile rats, the same concentration of norepinephrine raised the Ca²⁺ concentration from 32 ± 7.6 nM to 309 ± 46 nM (n = 4). The magnitude of the elicited responses, but not the resting Ca²⁺ levels, were significantly different between adult and juvenile rats. In both age groups, the responses could be abolished by prazosin (10 nM), indicating that they were mediated by α1-adrenoceptors. ρ-TIA inhibited the Ca²⁺ responses of adult cells with an IC₅₀ of 133 nM (pIC₅₀ = 6.88 ± 0.05) and juvenile cells with an IC₅₀ of 470 nM (pIC₅₀ = 6.33 ± 0.03) (Fig. 1). Neither curve’s bottom was significantly different from zero, indicating that ρ-TIA acts as a full inhibitor. The juvenile concentration-response curve was significantly steeper than the adult curve, with a Hill slope parameter of −2.6 ± 0.4 compared with −0.89 ± 0.10. ρ-TIA (1 μM) had no effect on the Ca²⁺ response of the isolated smooth muscle cells that was evoked by 10 μM ATP (n = 3; data not shown).

**α1-Adrenoceptor But Not α2-Adrenoceptor Antagonism**—The effect of various concentrations of ρ-TIA on the α1-adrenoceptor-mediated contractile responses of isolated segments of rat vas deferens to exogenously applied norepinephrine is shown in Fig. 2A. In the absence of ρ-TIA, the EC₅₀ of norepinephrine was determined to be 9.3 μM (pEC₅₀ = 5.0 ± 0.03). This value was increased to 32 μM (pEC₅₀ = 4.5 ± 0.07), 51 μM (pEC₅₀ = 4.3 ± 0.09), and to 166 μM (pEC₅₀ = 3.3 ± 0.08) in the presence of 1, 3, and 10 μM ρ-TIA, respectively. The maximum response of the tissue to norepinephrine was 99 ± 4.4% of the control response when 1 μM ρ-TIA was present and 82 ± 4.9% and 42 ± 3.4% in the presence of 3 and 10 μM ρ-TIA, respectively. The decline in the maximum response following treatment with the two highest concentrations of ρ-TIA was significant (p < 0.001).

The bisected rat prostatic vas deferens responded to electrical field stimulation with a biphasic contraction, reflecting the distinct time courses for the postsynaptic actions of the sympathetic co-transmitters ATP and norepinephrine in the tissue (20). Following the addition of prazosin, the previously biphasic response consisted of only the first component. This prazosin-resistant component could be abolished by activating α₂-adrenoceptors with exogenously applied norepinephrine. The IC₅₀ for the inhibition by norepinephrine was 1.1 μM (pIC₅₀ = 6.0 ± 0.10) (Fig. 2B). In the presence of ρ-TIA (10 μM), the IC₅₀ was not significantly different (pIC₅₀ = 5.9 ± 0.13). Neither norepinephrine nor ρ-TIA had a direct effect on the resting tension of the preparation.

**α1-Adrenoceptor Subtype Selectivity and Effect on [3H]prazosin Binding Kinetics—ρ-TIA inhibited the binding of [125I]HEAT to all three cloned α₁-adrenoceptor subtypes (Fig. 3). The IC₅₀ values for ρ-TIA were 150 nM (pIC₅₀ = 6.8 ± 0.04) at the α₁A-adrenoceptor; 70 nM (pIC₅₀ = 7.15 ± 0.06) at the α₁B-adrenoceptor; and 340 nM (pIC₅₀ = 6.5 ± 0.05) at the
presence of H11006 mean H11006 B) proceeded at a rate of 0.50 min analogs of H9267 effect of H9267 0.052 pmol/mg protein to 1.52 H11006 absence of H9267ponent of the biphasic contraction as observed for deferens assay, causing selective inhibition of the second component that remained after treatment with the an-

$\alpha_{1B}$-adrenoreceptor. The difference in the potency of $\rho$-TIA between $\alpha_{1A}$-adrenoreceptor subtypes was significant for all sets of comparisons ($p < 0.001$). The Hill slope parameters for the effect of $\rho$-TIA were not significantly different from unity. The effect of $\rho$-TIA on the association rate of $[^3H]$prazosin binding to $\alpha_{1B}$-adrenoreceptors is shown in Fig. 4A. In the absence of $\rho$-TIA, the observed rate constant for the association of $[^3H]$prazosin ($k_{oa}$) was determined to be $0.101 \pm 0.008$ min$^{-1}$. The $k_{oa}$ in experiments with $\rho$-TIA present was $0.119 \pm 0.013$ min$^{-1}$, which is not significantly different from the control value. The total specific binding was reduced from $2.50 \pm 0.052$ pmol/mg protein to $1.52 \pm 0.041$ pmol/mg protein in the presence of $\rho$-TIA (17.5 nM). The difference in the amount of total specific binding achieved in the absence and presence of $\rho$-TIA was highly significant ($p < 0.001$).

The dissociation of $[^3H]$prazosin from the $\alpha_{1B}$-adrenoreceptors (Fig. 4B) proceeded at a rate of $0.50 \pm 0.03$ h$^{-1}$ in control experiments. In the presence of $\rho$-TIA (10 $\mu$M), the dissociation rate constant ($k_{ot}$) was increased significantly to $1.15 \pm 0.06$ h$^{-1}$ ($p < 0.001$).

Truncated Analogs of $\rho$-TIA—All of the N-terminal truncated analogs of $\rho$-TIA (see Table I) tested were active in the vas deferens assay, causing selective inhibition of the second component of the biphasic contraction as observed for $\rho$-TIA. However, the N-terminal tail alone, TIA$_{1-5}$, had no effect on either phase of the contraction at a concentration of 10 $\mu$M. The deletion of N-terminal residues from $\rho$-TIA was associated with a loss in activity, demonstrated by the relative extent of the second component that remained after treatment with the ana-

DISCUSSION

As a peptide, $\rho$-TIA is structurally unique among the $\alpha_{1}$-adrenoreceptor antagonists described to date, some of which were also originally isolated from natural sources (e.g. the plant alkaloids corynanthine, dicentrine, and dehydroevodiamine). We have explored the pharmacology of $\rho$-TIA in functional and binding assays, and found that the uniqueness of $\rho$-TIA compared with other $\alpha_{1}$-adrenoreceptor antagonists also extends to its mechanism of action.

Functional $\alpha_{1}$-adrenoreceptor antagonism by $\rho$-TIA was demonstrated at both the tissue and cellular level through its ability to inhibit the norepinephrine-evoked increases in cytosolic free Ca$^{2+}$ concentration and contractility. The vast majority of known $\alpha_{1}$-adrenoreceptor antagonists act competitively with respect to norepinephrine. $\rho$-TIA, however, behaves as a non-competitive antagonist. This was indicated in these experiments by the effect of the peptide to inhibit the maximum level

![FIG. 2. Effect of $\rho$-TIA in functional assays for $\alpha_{1}$- and $\alpha_{2}$-adrenoreceptor antagonism. A, concentration-response curves for the contractile response elicited by the activation of $\alpha_{1}$-adrenoreceptors by exogenously applied norepinephrine measured in the absence (○) and presence of $\rho$-TIA (●, 1 $\mu$M; ▲, 3 $\mu$M; ■, 10 $\mu$M). B, concentration-response curves for the inhibition of the electrically evoked response of the rat vas deferens due to the activation of presynaptic $\alpha_{2}$-adrenoreceptors by exogenously applied norepinephrine measured in the absence (○) and presence (■) of 10 $\mu$M $\rho$-TIA. Symbols represent the mean ± S.E. of data from five experiments.](image)

![FIG. 3. Effect of $\rho$-TIA at $\alpha_{1}$-adrenoreceptor subtypes. Concentration-response curves for inhibition by $\rho$-TIA of the specific binding of the $\alpha_{1A}$-adrenoreceptor antagonist $[^{35}S] $HEAT to membranes from COS-1 cells transiently transfected with the rat $\alpha_{1A}$- (●), hamster $\alpha_{1H}$- (○), or rat $\alpha_{1H}$-adrenoreceptor (▲). Symbols represent the mean ± S.E. of data from three separate experiments performed in duplicate.](image)
of the $\alpha_1$-adrenoreceptor-mediated contractile response proving to be incapable of being surmounted by increasing the concentration of applied norepinephrine.

Changes in various aspects of $\alpha_1$-adrenergic neurotransmission associated with age have been reported (21–23), so potential age-related differences in the inhibitory action of $\rho$-TIA were examined. This was investigated in dissociated cells only, because the contractile response of the juvenile rat vas deferens is quite weak (24). $\rho$-TIA was $3.5 \times$ more potent at inhibiting $\text{Ca}^{2+}$ spikes following $\alpha_1$-adrenoreceptor activation by norepinephrine in cells from adult rats compared with those taken from juvenile rats. This might be due to an altered pattern of expression of $\alpha_1$-adrenoreceptor subtypes with age, as has been reported to occur in other tissues (25). Each of the three cloned $\alpha_1$-adrenoreceptor subtypes plays a functional role in the adult rat vas deferens (26–29), with the $\alpha_{1A}$ subtype generally agreed to be the principal mediator of responses to norepinephrine. The difference in potency of $\rho$-TIA in juvenile and adult rats is similar in magnitude to the range in potency across the three cloned $\alpha_1$-adrenoreceptors that was observed in the binding experiments. Involvement of the putative prazosin-insensitive $\alpha_{1L}$-adrenoreceptor described by Ohmura et al. (30) in influencing $\rho$-TIA potency, can, however, be ruled out as both adult and juvenile Ca$^{2+}$ responses were fully inhibited by a low dose of prazosin. Also, because the assays were performed using isolated smooth muscle cells, we can exclude the impact of changes in the effectiveness of the neuronal norepinephrine reuptake system that occur with age (31) as a reason for the disparate potency of $\rho$-TIA in juvenile and adult rats.

As well as the difference in potency, a change in the Hill slope of the concentration-response curve for $\rho$-TIA was seen between rats from the two age groups, with the data from

A.

![Graph 1](image1)

**Fig. 4.** Effect of $\rho$-TIA on the kinetics of [$^{3}\text{H}$]prazosin binding. A, association of [$^{3}\text{H}$]prazosin to $\alpha_{1a}$-adrenoreceptors over time in the absence (○) and presence (■) of 17.5 nM $\rho$-TIA. B, dissociation of [$^{3}\text{H}$]prazosin from $\alpha_{1a}$-adrenoreceptors over time in the absence (○) and presence (■) of 10 μM $\rho$-TIA. Symbols represent the mean ± S.E. of data obtained from three separate experiments. Some error bars are obscured by the symbols.

**Table 1**

| Peptide | Amino acid sequence | Connectivity |
|---------|---------------------|-------------|
| $\rho$-TIA | FNWRCCFLIPACRRNHKKFC* | 1–3, 2–4 |
| TIA$_{2-19}$ | NWRCFLIPACRRNHKKFC* | 1–3, 2–4 |
| TIA$_{3-19}$ | WRCCFLIPACRRNHKKFC* | 1–3, 2–4 |
| TIA$_{5-19}$ | RCCLIPACRRNHKKFC* | 1–3, 2–4 |
| TIA$_{1-5}$ | FNRCC* | none |

**Fig. 5.** $\alpha_1$-adrenoreceptor antagonist activity of $\rho$-TIA and its N-terminal truncated analogs. Comparison of the effect of $\rho$-TIA and the five truncated analogs (all 10 μM) on the magnitude of the noradrenergic component of the response of the rat vas deferens to electrical field stimulation. Bars represent the mean ± S.E. of results obtained from 3–5 experiments.

**Fig. 6.** Comparison of the potencies of $\rho$-TIA and its alanine-substituted analogs for the $\alpha_1$-adrenoreceptor. A series of analogs of $\rho$-TIA in which its non-cysteine residues were systematically replaced with alanine were assayed for inhibition of [$^{3}\text{H}$]prazosin binding to the membranes of COS-7 cells transfected with the hamster $\alpha_{1b}$-adrenoreceptor. Bars represent the mean ± S.E. of the analogs’ pIC$_{50}$ values determined from three concentration-response curves, with each concentration point on a single curve tested in triplicate. * indicates $p < 0.05$ and ** indicates $p < 0.001$ compared with $\rho$-TIA.

![Graph 2](image2)
Youthful animals exhibiting a much steeper inhibition profile. The relationship between $\alpha_1$-adrenoreceptor activation and functional response is known to be non-linear in the adult rat vas deferens (32, 33), giving rise to the phenomenon of “spare receptors,” and the efficiency of receptor-effector coupling is recognized to vary between $\alpha_1$-adrenoreceptor subtypes (34). Tighter receptor-effector coupling in the rat vas deferens of younger animals, with or without a change in the identity of the adrenoreceptor subtypes mediating the response, would act to reduce the apparent potency of a non-competitive inhibitor like $\rho$-TIA by requiring that a greater proportion of the receptor pool be inactivated to achieve the same level of inhibition. Furthermore, the concentration-response curve for inhibition would steepen as the relationship between receptor activation and response became more strongly hyperbolic. Our observation that the norepinephrine-evoked $\text{Ca}^{2+}$ responses of cells from juvenile animals were substantially larger than those of older animals may indicate a decline in $\alpha_1$-adrenoreceptor signaling efficiency with age. The presence of spare receptors in the adult rat vas deferens explains why $\rho$-TIA initially shifted the concentration-response curve for norepinephrine to the right without an accompanying decline in the maximum response, as was evident in the presence of the two higher concentrations of $\rho$-TIA.

In light of $\rho$-TIA's modest $\alpha_1$-adrenoreceptor subtype selectivity, it was of interest to investigate whether $\alpha_2$-adrenoreceptors were a target of $\rho$-TIA. The finding that $\rho$-TIA (10 $\mu$m) did not protect the evoked responses from inhibition by norepinephrine, as $\alpha_2$-adrenoreceptor antagonists such as yohimbine have been demonstrated to do in this assay (35), indicates that the peptide does not block $\alpha_2$-adrenoreceptors.

To investigate the mode of action of $\rho$-TIA at the $\alpha_1$-adrenoreceptor, the effect of $\rho$-TIA on the kinetics of $[^{3}H]$prazosin binding to the receptor was examined. The $\alpha_{1B}$ subtype was used as the prototypical $\alpha_1$-adrenoreceptor in these experiments because it is at this subtype that $\rho$-TIA displays the highest potency. Confirming that $\rho$-TIA does not block the $\alpha_1$-adrenoreceptor through a competitive interaction, the rate constant observed for the association of $[^{3}H]$prazosin to $\alpha_1$-adrenoreceptors was unchanged in the presence of $\rho$-TIA and not reduced as would have been expected if the conopeptide acted competitively. The decline in the amount of equilibrium binding without a change in the rate constant for association when $\rho$-TIA was included in the binding reaction is consistent with the conopeptide disrupting $[^{3}H]$prazosin binding through an allosteric interaction. We suggest then that the agonist binding site, which is recognized by norepinephrine and competitive antagonists such as HEAT and prazosin, and the $\rho$-TIA site on the $\alpha_1$-adrenoreceptor are distinct. Upon binding of $\rho$-TIA to its site on the $\alpha_1$-adrenoreceptor, the receptor loses its ability to recognize agonists and competitive antagonists through an allosteric action of $\rho$-TIA to disrupt the structure of the agonist-binding site, reducing the size of the pool of available receptors for these ligands.

The increase in the rate of dissociation of $[^{3}H]$prazosin from the $\alpha_1$-adrenoreceptor in the presence of $\rho$-TIA reveals that the conopeptide can still bind to the receptor when $[^{3}H]$prazosin is already bound and that $\rho$-TIA promotes the dissociation of $[^{3}H]$prazosin from the receptor. The R$\rho$-TIA/prazosin complex can not be distinguished from the Rprazosin complex in these experiments because both species are radiolabelled. Consequently, the rate of dissociation observed in the presence of $\rho$-TIA reflects a combination of the rates of $[^{3}H]$prazosin dissociation from both the Rprazosin and the R$\rho$-TIA/prazosin complexes. The relative contribution of each dissociation reaction to the overall rate that is measured depends on the two rate constants and also the relative concentrations of Rprazosin and R$\rho$-TIA/prazosin. The modest increase in the observed rate (2.3 times faster) in the presence of a high concentration of $\rho$-TIA, which fully inhibits specific $[^{3}H]$prazosin equilibrium binding (10 $\mu$m), might indicate that the affinity of $\rho$-TIA for the $\alpha_1$-adrenoreceptor is lower when $[^{3}H]$prazosin is bound than it is for the unoccupied receptor. Such a situation would represent bidirectional negative allosteric modulation between the competitive antagonist and $\rho$-TIA binding sites.

In addition to the $\rho$-conopeptides, two other classes of allosteric modulators of the $\alpha_1$-adrenoreceptor have been reported, but neither act in the same manner as $\rho$-TIA. The allosteric effect of the benzodiazepines diazepam, lorazepam, and midazolam at the $\alpha_1$-adrenoreceptor was reported by Waugh et al. (36). These agents are better known for their allosteric effect at the $\gamma$-aminobutyric acid $\alpha_1$ receptor, where they do not activate the receptor themselves, but act to increase the affinity and efficacy of the endogenous agonist GABA (37, 38). Like $\rho$-TIA, these three benzodiazepines were found to inhibit $[^{125}I]$HEAT binding, although much less potently, with IC$_{50}$ values at the human $\alpha_1$-adrenoreceptor subtypes of ~100 $\mu$m (36). Unlike $\rho$-TIA, however, the benzodiazepines were found to act as weak partial agonists of $\alpha_1$-adrenoreceptors by themselves in functional assays, and to increase the maximum response and EC$_{50}$ of both full and partial $\alpha_1$-adrenoreceptor agonists. This indicates a dual allosteric effect of the benzodiazepines to simultaneously reduce the affinity of the agonist-binding site for ligand and to increase the affinity of the agonist-bound form of the receptor for G-protein, effects not observed with $\rho$-TIA. The other class of $\alpha_1$-adrenoreceptor allosteric modulators are the amiloride analogs. Leppik et al. (39) found that amiloride and its analogs increased the rate of dissociation of $[^{3}H]$ prazosin from the $\alpha_1$-adrenoreceptor, as $\rho$-TIA does here. However, the amiloride analogs were found not to inhibit the saturability of radioligand binding as has been shown to occur with $\rho$-TIA (4). This implies that the allosteric effect of the amiloride analogs on the structure of the competitive antagonist-binding site is more subtle than that of $\rho$-TIA, with the conopeptide seemingly abolishing the binding site rather than merely changing its structure so that the receptor can still recognize the ligands only with less affinity.

Our attempts to gain an insight into the structural basis for $\rho$-TIA’s $\alpha_1$-adrenoreceptor antagonist activity initially focused on the N-terminal region of the peptide. This section
was chosen for study because it displays the least homology to the \( \alpha \)-conopeptides, a class whose members are, structurally, otherwise quite similar to \( \rho \)-TIA but do not block \( \alpha_1 \)-adrenoceptors. We found that the N-terminal region of \( \rho \)-TIA alone is not sufficient for \( \alpha_1 \)-adrenoceptor antagonist activity, demonstrated by the lack of activity of the TIA1-5 analog. The sequential removal of the first three residues of \( \rho \)-TIA had a small detrimental effect on activity, but it was sub-
sequent removal of the fourth residue of full-length \( \rho \)-TIA in the form of the analog TIA1-19 that the largest impact on activity was seen. Assuming that TIA1-19 acts with a Hill slope of unity, the observation that 65% of the response remains after treatment with the analog at a concentration of 10 \( \mu M \) implies that TIA1-19 is a 34-fold less potent than full-
length \( \rho \)-TIA. Thus, a substantial role for the residue located in position 4 of \( \rho \)-TIA in conferring \( \alpha_1 \)-adrenoceptor activity on \( \rho \)-TIA is indicated. This was also the conclusion to be drawn from the results of the alanine walk of \( \rho \)-TIA, where the substitution of Arg4 with alanine had the largest impact on \( \alpha_1 \)-adrenoceptor antagonist potency of all the replace-
ments made. Residue replacement has little effect on the robust structures of the \( \alpha \)-conopeptides, so it would be expected that \( \rho \)-TIA will behave similarly given the structural similarity between the two conopeptide classes. The three-
dimensional structure of \( \rho \)-TIA (Fig. 7) shows that the Arg4 sidechain is exposed and surrounded by a cluster of other residues also identified in the alanine walk to contribute to \( \rho \)-TIA’s \( \alpha_1 \)-adrenoceptor antagonist activity. The import-
ance of Arg4 could reflect an interaction of the positive charge of this side chain with a complementary negatively charged residue on the \( \alpha_1 \)-adrenoceptor. The small degree of subtype selectivity possessed by \( \rho \)-TIA implies that its binding site is conserved across \( \alpha_1 \)-adrenoceptors, and given the size and chemical nature of \( \rho \)-TIA, we expect that this site is located on an extracellularly exposed portion of the receptor. The \( \alpha_{1A} \), \( \alpha_{1B} \), and \( \alpha_{1D} \)-adrenoceptor subtypes display 32% sequence identity in their predicted extra-
cellular domains (40), with several conserved negatively charged residues present.

In summary, the venom peptide \( \rho \)-TIA acts as a reversible, non-competitive \( \alpha_1 \)-adrenoceptor antagonist with some sub-
type selectivity. The discovery of a peptide ligand that disrupts \( \alpha_1 \)-adrenoceptor operation raises the possibility that endog-
ogenous peptides or proteins that act in the same manner might exist. The endogenous circulating factor implicated by Shapiro et al. (41) in the pathogenesis of sympathotonic orthostatic hypotension may be such a compound. In addition, the eluci-
dation and characterization of a peptide that allosterically in-
hibits \( \alpha_1 \)-adrenoceptors by interacting with residues distinct from those of the poorly selective classical inhibitors suggests that the development of highly subtype-selective compounds should be feasible. Such agents are likely to have major ther-
apeutic advantages over the existing ligands.

\(^{2}\) R. J. Lewis and P. F. Alewood, unpublished observations.

---

**Acknowledgments**—We thank Trudy Milne, Sebastien Dutertre, and John Gehrmann (Institute for Molecular Bioscience, The University of Queensland) for their assistance.

**REFERENCES**

1. Langer, S. Z., and Shepperson, N. B. (1982) J. Cardiovasc. Pharmacol. 4, S8–S13
2. Tammela, T. (1997) Drugs Aging 10, 349–366
3. Olivera, B. M., and Cruz, L. J. (2001) Toxicon 39, 7–14
4. Sharpe, I. A., Gehrmann, J., Loughman, M. L., Thomas, L., Adams, D. A., Atkins, A., Palant, E., Craik, D. J., Adams, D. J., Alewood, P. F., and Lewis, R. J. (2001) Nature Neurosci. 4, 902–907
5. Martinez, J. S., Olivera, B. M., Gray, W. R., Craig, A. G., Groebe, D. R., Abramson, S. N., and McIntosh, J. M. (1995) Biochemistry 34, 14519–14526
6. Favreau, P., Krimm, Y., Le Gall, F., Borensztein, M. J., Lamthan, H., Bouet, F., Servent, D., Molgo, J., Menex, A., Letourneux, Y., and Lancelin, J. M. (1999) Biochemistry 38, 6317–6326
7. McIntosh, J. M., Cruz, L. J., Hankapiller, M. W., Gray, W. R., and Olivera, B. M. (1982) Arch. Biochem. Biophys. 218, 329–334
8. Nicke, A., Loughnan, M. L., Millard, E. L., Alewood, P. F., Adams, D. J., Daly, N. L., Craik, D. J., and Lewis, R. J. (2002) J. Biol. Chem. 278, 3137–3144
9. Schnolzer, M., Alewood, P., Jones, A., Alewood, D., and Kent, S. B. (1999) Int. J. Pept. Protein Res. 40, 180–193
10. Sarin, V. K., Kent, S. B., Tam, J. P., and Merrifield, R. B. (1981) J. Biol. Chem. 256, 1407–1408
11. Chen, S., Lin, F., Xu, M., Hwa, J., and Graham, R. M. (2000) EMBO J. 19, 4265–4271
12. Perez, D. M., Piacsek, M. T., Malik, N., Gaivin, R., and Graham, R. M. (1994) Mol. Pharmacol. 46, 823–831
13. Hwa, J., Graham, R. M., and Perez, D. M. (1995) J. Biol. Chem. 270, 21389–21396
14. Perez, D. M., Piacsek, M. T., and Graham, R. M. (1991) Mol. Pharmacol. 40, 876–883
15. Bradford, M. M. (1976) Anal. Biochem. 72, 248–254
16. MacDonald, A., and McGrath, J. C. (1984) Br. J. Pharmacol. 82, 25–34
17. Takayanagi, I., Shinkai, M., and Yamasawa, K. (1989) Can. J. Physiol. Pharmacol. 67, 1298–1402
18. Chen, S., Lin, F., Xu, M., Hwa, J., and Graham, R. M. (2000) EMBO J. 19, 4265–4271
19. Perez, D. M., Piacsek, M. T., Malik, N., Gaivin, R., and Graham, R. M. (1994) Mol. Pharmacol. 46, 823–831
20. Hwa, J., Graham, R. M., and Perez, D. M. (1995) J. Biol. Chem. 270, 21389–21396
21. Alou, R., Shafii, M., and Docherty, J. R. (1993) Br. J. Pharmacol. 109, 80–87
22. Burt, R. P., Chapple, C. R., and Marshall, I. (1998) Br. J. Pharmacol. 123, 317–325
23. Honner, V., and Docherty, J. R. (1999) Br. J. Pharmacol. 128, 1325–1331
24. Millard, N. J., Marshall, I., Douglas, A. J., and Spriggs, T. L. B. (1992) Br. J. Pharmacol. 105, 727–734
25. Ohmura, T., Oshita, M., Kigoshi, S., and Muramatsu, I. (1992) Br. J. Pharmacol. 107, 697–704
26. de Avellar, M. C., Kobashi, Y. L., and Markus, R. P. (1990) Naunyn-Schmiede-
berg’s Arch. Pharmacol. 341, 295–300
27. Diaz-Toledo, A., and Marti, M. C. (1988) Eur. J. Pharmacol. 156, 315–324
28. Minneman, K. P., and Abel, P. W. (1984) Mol. Pharmacol. 25, 56–63
29. Theroux, T. L., Esbenshade, T. A., Peavy, R. D., and Minneman, K. P. (1996) Mol. Pharmacol. 50, 1376–1387
30. Leedham, J. A., and Pennefather, J. (1982) Br. J. Pharmacol. 77, 283–289
31. Waugh, D. J., Gaivin, R. J., Damron, D. S., Murray, P. A., and Perez, D. M. (1999) J. Pharmacol. Exp. Ther. 291, 1164–1171
32. Costa, E., Guidotti, A., and Mao, C. C. (1975) Adv. Biochem. Psychopharmacol. 14, 113–130
33. Haefely, W., Kuczak, A., Mohler, H., Pieri, L., Pole, P., and Schaffner, R. (1975) Adv. Biochem. Psychopharmacol. 14, 131–151
34. Lepak, R. A., Mynett, A., Lazarro, S., and Birdsell, N. J. (2000) Mol. Pharmacol. 57, 436–445
35. Graham, R. M., Perez, D. M., Hwa, J., and Piacsek, M. T. (1996) Circ. Res. 78, 737–749
36. Shapiro, R. E., Winters, B., Hales, M., Barnett, T., Schwinn, D. A., Flavahan, N., and Berkowitz, D. E. (2000) Hypertension 36, 553–560
